Abstract: The present invention relates to a gastro-resistant pharmaceutical composition comprising a solid solution prepared by hot-melt extrusion, whereby the solid solution contains posaconazole, an enteric polymer and a non-enteric polymer. The composition is preferably a granulate material that can be filled into a capsule or compressed into a tablet.

Abstract: A functional food including a supplement composition in which the supplement composition includes a non-winterized marine source oil.

Abstract: An oriental shampoo composition that can help maintain the health of the scalp and hair and help alleviate hair loss is provided. The shampoo composition includes, among others, 47.89% by weight of purified water; 10.00% by weight of a herbal mixed solution containing purified water, Rehmannia chinensis root extract, butylene glycol, Mentha arvensis extract, 1,2-hexanediol, Acorus gramineus root extract, Biota orientalis leaf extract, Chrysanthemum zawadskii extract, Panax ginseng root extract, Glycyrrhiza galbra (licorice) root extract, Lycinum chinense fruit extract, Morus alba bark extract, Xanthium strumarium fruit extract, and ethyl hexyl glycerin; 10.00% by weight of a mixed solution containing sodium lauryl sulfate, purified water, disodium phosphate and sodium carbonate; 10.00% by weight of a mixed solution containing purified water, TEA-lauryl sulfate and sodium benzoate; and 8.0% by weight of a mixed solution containing purified water, cocamidopropyl betaine and sodium chloride.

Abstract: Methods and compositions for improving the appearance of skin are provided. The methods and compositions are especially suited for improving sallow-looking skin by enhancing bilirubin degradation in skin. The methods and compositions herein utilize one or more sucrose esters, which demonstrate a surprising ability to reduce bilirubin levels. The method involves applying a skin care composition containing an effective amount of a sucrose ester to a target portion of skin where a reduction in bilirubin level is desired.

Abstract: Embodiments of the present invention provide improved livestock foot bath solutions that are capable of maintaining a low pH during longer periods of use in order to help prevent the metal salts from precipitating out of the solution and rendering the solution ineffective. Embodiments of the present invention provide improved livestock foot bath solutions that include one or more weak organic acids, such as polyprotic organic acids, in the aqueous solution, along with the dissolved metal salts. Embodiments of the invention may also include sulfuric acid, or some other strong acid, together with citric acid and the dissolved metal salts in the aqueous solution.

Abstract: The present invention relates to topical compositions comprising D-panthenol, bis-ethylhexyloxyphenol methoxyphenyl triazine (BEMT) and hydroxyacetophenone (HAP) in specific weight ratios which show less staining.

Abstract: The present disclosure is in the field of gastroretentive dosage forms. A gastroretentive dosage form for extended retention in a stomach is provided.

Abstract: Methods of manufacturing tissue interfacing components, such as solid needles comprising one or more therapeutic agents, are disclosed. In some embodiments, a method for manufacturing a tissue interfacing component comprises compressing a granular therapeutic agent within a mold cavity of a mold to form a solid tissue interfacing component. The mold cavity may define an elongated shape extending along a longitudinal axis from an opening of the mold cavity to a distal end of the mold cavity, and the granular therapeutic agent may be compressed by moving a mold punch along the longitudinal axis towards the distal end. After compressing the granular therapeutic agent to form the solid tissue interfacing component, the tissue interfacing component may be removed from the mold and subsequently inserted into tissue to deliver the therapeutic agent to a subject.

Abstract: The present invention relates to topical compositions comprising panthenol, hydroxyacetophenone and a micronized UV filter.

Abstract: The present disclosure provides a method for manufacturing a porous film, including: preparing a polymer mixture solution, wherein the polymer mixture solution includes polycaprolactone and at least one hydrophobic polymer; adding solid particles as a dispersing agent to the polymer mixture solution and mixing the solid particles with the polymer mixture solution, wherein the amount of solid particles added is enough to convert the polymer mixture solution into a solid mixture; drying the solid mixture to form a film; and washing the film with a washing fluid to remove the solid particles from the film to form the porous film, wherein the weight ratio of the polycaprolactone to the at least one hydrophobic polymer is about 1:0.1-10, and wherein the weight ratio of the polycaprolactone and the at least one hydrophobic polymer to the solid particles is about 1:0.01-250.

Abstract: A peptide having the general Formula (1) X-(Xaa)nK*TFK*-(Xaa)m-Z??(1) is described, where the peptide helps preserve or improve the condition of the epidermis and wherein X, (Xaa)n, (Xaa)m, n, m, K* and Z are as defined.

Abstract: The present invention relates to a composition, especially a cosmetic, in particular photoprotective, composition, comprising at least: —one or more particular acrylic polymers —one or more fatty acid esters of dextrin, and —one or more UV-screening agents.

Abstract: A kit for enabling delivery of an active compound to the skin for penetration into the skin, a delivery device for delivering an active compound, and a method of delivery of an active compound are provided. An active compound delivery kit for enabling delivery of an active compound into the skin of a subject includes an arrangement for providing a pathway into a biological barrier of a subject in an application zone, an active compound provided in dry form, and a delivery device for delivery of dissolved active compound to the application zone. Provision of a pathway into the biological barrier, preferably skin, is provided and the active compound applied in optimum form within a short time frame after forming the pathway ensuring treatment of the desired skin cells is optimised.

Abstract: Various embodiments disclosed relate to drug-coated balloon catheters for treating, preventing, or reducing the recurrence of a stricture and/or cancer, or for treating benign prostatic hyperplasia (BPH), in a non-vascular body lumen and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent. In some embodiments, the balloon catheter includes a length-control mechanism which stretches and elongates the balloon when it is in a deflated state, giving the balloon a smaller cross-sectional deflated profile for tracking through the body lumen and for removal after treatment.

Abstract: Compositions contain boron nitride nanomaterials at least partially coated with biomolecules.

Abstract: A plant growth promoting agent which contains cellulose nanofibers and which is directly or indirectly applied to, sprinkled on, or sprayed on a plant. By using cellulose nanofibers having a specific average fiber diameter and a specific average fiber length, agglomeration of the cellulose fibers is thereby suppressed. This enables efficient insecticidal effect to be realized, wherein the insecticidally active ingredient is a non-chemosynthetic material.

Abstract: Embodiments of the present invention provide a method of treating a stricture in a nonvascular body lumen such as urethral strictures, benign prostatic hyperplasia (BPH) strictures, ureteral strictures, esophageal strictures, sinus strictures, and biliary tract strictures. Embodiments of the present invention provide a method for treating at least one of benign prostatic hyperplasia (BPH), prostate cancer, asthma, and chronic obstructive pulmonary disease (COPD). The method can include delivering, for example, via drug coated balloon catheters, anti-inflammatory and anti-proliferative drugs (e.g., rapamycin, paclitaxel, and their analogues) and one or more additives.

Abstract: The present invention is directed to transdermal therapeutic systems that are free of fibrous constituents, as well methods for producing such transdermal therapeutic systems. A preparation containing active substance is applied by a printing method onto the pressure-sensitive adhesive layer of the transdermal therapeutic system. Exemplary printing methods include application methods based upon a distributor plate of an application device.

Abstract: Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.

Abstract: Disclosed is a non-spherical microcapsule comprising a core comprising a benefit agent, and a shell comprising nanoparticles having a diameter of 10 to 300 nm and polyurea.